Millipore Sigma Vibrant Logo

OP19 Anti-c-Abl (Ab-2) Mouse mAb (19-110)

Anti-c-Abl (Ab-2) Mouse mAb (19-110): Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: Anti-p150, Anti-Abl

View Products on Sigmaaldrich.com
OP19
  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Maximum Quantity is
Al finalizar el pedido Más información
Ahorró ()
 
—
Solicitar precio
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Descripción

      Replacement Information

      Tabla espec. clave

      Species ReactivityHostAntibody Type
      H, MMMonoclonal Antibody
      Description
      Overview

      This product has been discontinued.



      Recognizes the ~145 kDa human c-Abl, the ~150 kDa mouse c-Abl, v-Abl proteins, and the Bcr/Abl translocation products in ALL (~190 kDa) and CML (~210 kDa).

    • Antibody Target Gene Symbol: ABL1
    • Target Synonym: ABL, AI325092, bcr/abl, C-ABL, C-ABL 1B, CABL1, E430008G22Rik, JTK7, MGC117749, p145Abl, p150, v-abl
    • Entrez Gene Name: c-abl oncogene 1, receptor tyrosine kinase
    • Hu Entrez ID: 25 (Related Antibodies: OP20 PK1006 PK1013)
    • Mu Entrez ID: 11350
    • Rat Entrez ID: 311860
      		•
      Catalogue NumberOP19
      Brand Family Calbiochem®
      SynonymsAnti-p150, Anti-Abl
      References
      ReferencesWiedemann, L.M., et al. 1988. Blood 71, 349.
      Schiff-Maker, L., Buet al. 1986. J. Virol. 57, 1182.
      Stam, K., et al. 1985. N. Engl. J. Med. 313, 1429.
      Konopka, J.B., et al. 1984. Cell 37, 1035.
      Prywes, R., et al. 1983. Cell 34, 569.
      de Klein, et al. 1982. Nature 300, 765. 1982.
      Reynolds, F.H., et al. 1980. J. Virol. 36, 374.
      Reynolds, F.H., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 3974.
      Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 2488. 1978.
      Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res. 30, 2213.
      Product Information
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin.
      Positive controlK562 (human bcr/abl protein), ANN-1 (mouse abl protein), HL-60 (human normal abl protein), or NIH 3T3 (mouse normal abl protein) cells
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application ReferencesNeutralization Studies, Original Clone Schiff-Maker, L., Buet al. 1986. J. Virol. 57, 1182.
      Key Applications Immunoblotting (Western Blotting)
      Immunoprecipitation
      Neutralization Studies
      Application NotesImmunoblotting (1-5 µg/ml)
      Immunoprecipitation (1-2 µg/sample)
      Neutralization Studies (see application references)
      Application CommentsInhibits tyrosine kinase activity (see application references). Antibody should be titrated for optimal use in individual systems.
      Biological Information
      Immunogena TrpE-v-Abl fusion protein
      Clone19-110
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      • Mouse
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      OP19 0

      Documentation

      Anti-c-Abl (Ab-2) Mouse mAb (19-110) Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Anti-c-Abl (Ab-2) Mouse mAb (19-110) Certificados de análisis

      CargoNúmero de lote
      OP19

      Referencias bibliográficas

      Visión general referencias
      Wiedemann, L.M., et al. 1988. Blood 71, 349.
      Schiff-Maker, L., Buet al. 1986. J. Virol. 57, 1182.
      Stam, K., et al. 1985. N. Engl. J. Med. 313, 1429.
      Konopka, J.B., et al. 1984. Cell 37, 1035.
      Prywes, R., et al. 1983. Cell 34, 569.
      de Klein, et al. 1982. Nature 300, 765. 1982.
      Reynolds, F.H., et al. 1980. J. Virol. 36, 374.
      Reynolds, F.H., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 3974.
      Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 2488. 1978.
      Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res. 30, 2213.

      Folleto

      Cargo
      Antibody Sourcebookﾙ Sixth Edition
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision26-February-2008 JSW
      SynonymsAnti-p150, Anti-Abl
      ApplicationImmunoblotting (1-5 µg/ml)
      Immunoprecipitation (1-2 µg/sample)
      Neutralization Studies (see application references)
      DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specifed immunogen and fusing splenocytes with P.3U1 mouse myeloma cells (see application references). Recognizes the v-abl, CML c-brc/abl p210, human ALL c-brc/abl p190, human c-abl p145, and mouse c-abl p150 proteins.
      BackgroundThe abl oncogene was initially identified as the viral transforming gene (v-abl) of Abelson murine leukemia virus (A-MuLV), from a chemically thymectomized mouse inoculated with Moloney murine leukemia virus (M-MuLV). The v-abl genome consists of M-MuLV gag sequences fused to mouse c-abl, resulting in the production of gag/c-abl tyrosine kinases, phosphoproteins p160 and p120, as the major translational products. The abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic (CML), 20-25% of adult acute lymphoblastic (ALL) and 2-5% of pediatric ALL. In these leukemias the c-abl proto-oncogene undergoes a chromosomal translocation producing the Philadelphia (Ph1) chromosome resulting in the fusion of c-abl sequences to the bcr gene of chromosome 22. The molecular consequences of this translocation are the generation of a chimeric bcr/c-abl mRNA encoding activated abl protein-tyrosine kinase.
      HostMouse
      Immunogena TrpE-v-Abl fusion protein
      Clone19-110
      IsotypeIgG₁
      Specieshuman, mouse
      Positive controlK562 (human bcr/abl protein), ANN-1 (mouse abl protein), HL-60 (human normal abl protein), or NIH 3T3 (mouse normal abl protein) cells
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsInhibits tyrosine kinase activity (see application references). Antibody should be titrated for optimal use in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      ReferencesWiedemann, L.M., et al. 1988. Blood 71, 349.
      Schiff-Maker, L., Buet al. 1986. J. Virol. 57, 1182.
      Stam, K., et al. 1985. N. Engl. J. Med. 313, 1429.
      Konopka, J.B., et al. 1984. Cell 37, 1035.
      Prywes, R., et al. 1983. Cell 34, 569.
      de Klein, et al. 1982. Nature 300, 765. 1982.
      Reynolds, F.H., et al. 1980. J. Virol. 36, 374.
      Reynolds, F.H., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 3974.
      Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 2488. 1978.
      Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res. 30, 2213.
      Application referencesNeutralization Studies, Original Clone Schiff-Maker, L., Buet al. 1986. J. Virol. 57, 1182.